Medical/Pharmaceuticals
Antengene Unveils Its First Australian Office to Continue Expanding Global Presence
SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Antengene recently unveileda new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help An...
2022-09-14 08:30
3295
Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future LAUSANNE, Switzerland, Sept. 14, 2022 /PRNewswire/ -- Debiopharm Innovation Fund, the strategic investm...
2022-09-14 00:48
1423
New Study by Lunit and MGH Validates Effectiveness of AI as Aid in Chest X-Ray Interpretation - Published in JAMA Network Open
* Joint study with Massachusetts General Hospital proves that Lunit's
AI-powered chest x-ray analysis software enhances the overall performance and
efficiency of radiologists SEOUL, South Korea, Sept. 13, 2022 /PRNewswire/ -- A
recent study published in
2022-09-13 22:16
1231
TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism
BIRMINGHAM, England, Sept. 13, 2022 /PRNewswire/ -- Concept Medical
2022-09-13 22:15
1781
AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101
An oral Tyrosine Kinase Inhibitor of HER2 Exon20 Insertion, for the Treatment of Non-Small Cell Lung Cancer TAIPEI, Sept. 13, 2022 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients, announ...
2022-09-13 22:00
1860
EDGC (Eone Diagnomics Genome Center) recruits Sam Martin, Vice President of Overseas Business Development... to "accelerate entering the overseas market"
* An expert from Invitae and Ambry Genetics, U.S. genome analysis companies * EDGC states, "We will expand the overseas genome analysis market and advance into the global liquid biopsy technology market by recruiting a global talent in the genome field" * Worked in a non-profit research orga...
2022-09-13 21:00
1359
Turn Biotechnologies launches eTurna™ delivery platform designed specifically to enable nucleic acid therapeutics
The proprietary platform is versatile, equally effective with different cargoes, routes of administration MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today ann...
2022-09-13 20:38
1582
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (...
2022-09-13 20:00
2068
AO Foundation acquires RIMASYS to advance the surgical education ecosystem of the future
DAVOS, Switzerland and COLOGNE, Germany, Sept. 13, 2022 /PRNewswire/ -- The AO
Foundation and RIMASYS are pleased to announce that they have taken their
strategic partnership to the next level with a full-stake investment by the AO
in RIMASYS.
2022-09-13 18:00
1509
TikoMed's ILB(R) inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro
Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies VIKEN, Sweden, Sept. 13, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the company's lead drug candid...
2022-09-13 16:08
1546
SmartFuture's White-label Remote Patient Monitoring Platform goes global
SINGAPORE, Sept. 13, 2022 /PRNewswire/ -- SmartFuture's white-label Remote Patient Monitoring (RPM) platform is now being deployed successfully in 11 countries, includingSingapore, Malaysia, other ASEAN countries, India and most recently, inthe United States. According to Sumit Khemani, CEO, "...
2022-09-13 16:03
2607
First and only TIGIT/TGF-β dual-targeting antibody fusion protein of Akeso demonstrated promise in preclinical results published at ESMO
HONG KONG, Sept, 13, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, published encouraging preclinical results in poster featuring its F...
2022-09-13 14:02
1033
Microtech to unveil implantable microsensor technology at 34th Transcatheter Cardiovascular Therapeutics (TCT) annual meeting
TEL AVIV, Israel, Sept. 13, 2022 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol, Inc., a leader in global MedTech research and development, announced that its implantable microsensor platform will be presented at the34th Transcatheter Cardiovascular Therapeutics (TCT), the annua...
2022-09-13 09:11
1471
CStone announces China's NMPA has accepted and granted priority review to the supplemental new drug application (sNDA) for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
* This is the third supplemental new drug application (NDA) that CStone has submitted for sugemalimab after the prior two for stage III and IV non-small cell lung cancer. Sugemalimab has the potential to become the world's first immuno-oncology therapy to be approved for patients with relapsed ...
2022-09-13 08:02
2768
Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022
* In first line treatment of advanced or metastatic G/GEJ cancer, early interim data of the first 15 patients with measurable disease receiving the combination of TST001 (Osemitamab) with CAPOX demonstrated a partial response rate of 73.3% and a disease control rate of 100% per RECIST1.1. * B...
2022-09-13 08:00
2129
Starpharma presents compelling data in Prostate Cancer at ESMO
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP® cabazitaxel is a patented, highly water soluble dendrimer nanopartic...
2022-09-13 06:28
1416
NCCN's New Patient Guidelines for Marginal Zone Lymphoma Help Patients and Caregivers Better Understand a Rare Form of Blood Cancer
An evidence-based, expert consensus resource, available for free at NCCN.org/patientguidelines, helps people understand a rare and complex cancer type PLYMOUTH MEETING, Pa., Sept. 13, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for P...
2022-09-13 00:35
1379
Aldatu Biosciences Adds Another Outbreak Disease to Pandemic Preparedness Portfolio
BOSTON, Sept. 13, 2022 /PRNewswire/ -- Aldatu Biosciences, a biotechnology company developing molecular diagnostic assays and products based on gold standard real-time PCR, today announced it has been awarded a$3 Million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the ...
2022-09-13 00:33
1382
DarwinHealth Publication Reports Step-by-Step Protocol for its Tumor Checkpoint-Based, Compound-to-Clinic (C2C) Cancer Drug Discovery Pipeline: Elucidates a Patient-to-Model-to-Patient (PMP) Roadmap for Precision- and Mechanism-Based Identification and Clinical Validation of Novel, Investigational and FDA-Approved Therapeutic Agents Targeting Tumor Regulatory Architecture
NEW YORK, Sept. 13, 2022 /PRNewswire/ -- DarwinHealth, Inc., ( www.DarwinHealth.com) a New York-based biotechnology and cancer drug discovery company announces theSeptember 9, 2022 online publication in Current Protocols (Wiley Science) of their proprietary cancer drug discovery and validation pi...
2022-09-13 00:26
1780
EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products
PROVIDENCE, R.I., Sept. 13, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce the award of a two-year,$2 million grant from the FDA's Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk assessment of host cell proteins (HCP) for ...
2022-09-13 00:24
1561
Week's Top Stories
Most Reposted
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 318 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 302 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
[Picked up by 272 media titles]
2024-05-10 15:20
Where does China's production capacity come from?
[Picked up by 258 media titles]
2024-05-10 12:01Most Read
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
8752
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
2024-05-10 15:20
8117
Where does China's production capacity come from?
2024-05-10 12:01
7954
China Jo-Jo Drugstores Announces $2.74 Million Registered Direct Offering
2024-05-10 21:20
4980